DEXLEVO
22.6.2022 13:23:05 CEST | Business Wire | Press release
GS, which has announced its expansion into the bio business by acquiring Hugel, a botulinum toxin manufacturer, now seeks further business expansion. The group plans to diversify its business portfolio by collaborating with technology-competitive bio ventures. Recently, it is seen to consider synergy by combining botulinum toxin and fillers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220621005613/en/
According to industry sources, GS’s trading arm GS Global is exploring the global filler market by signing a strategic partnership with DEXLEVO on May 20. The agreement worth 10 million dollars (KRW 12.7 billion) aims to distribute GOURI, a liquid PCL injectable of DEXLEVO in Turkey. GS is also eyeing penetrating markets in Europe and the Greater China Region.
GS focuses on DEXLEVO’s superior technology which can generate synergy with its bio portfolio. GOURI is the world’s first filler based on polycaprolactone (PCL), a biodegradable solubilized polymer. The product evenly spreads to human faces without particles after injection to form collagen.
Furthermore, the group noted the fact that filler and botulinum are complementary goods under the same aesthetic portfolio. DEXLEVO’s product GOURI received CE certification in May 2021, paving the way for exports. GS intends to export Hugel’s botulinum toxin utilizing the distribution network for DEXLEVO’s filler.
Industry officials said that Hugel had built a relationship with DEXLEVO by securing the right to exclusive distribution of DEXLEVO’s liquid polymer fillers in Korea before it was acquired by GS, and thus GS is expecting synergy when it expands the botulinum toxin business.
GS has made various moves to expand its bio business. Last year GS Global signed a business agreement with AT Sens, a developer of ECG (electrocardiogram) monitors to explore the North American market. The agreement was to sell AT-Patch, the first long-term uninterrupted ambulatory cardiac monitor launched in Korea by AT Sens to North America.
In addition, the Future Business Team of the holding company GS is exploring new businesses to seek additional sources of growth through M&A. Future business Team consists of team leader Hur Seo-Hong, and Executive Directors Gwak Won Cheol, Hwang Jae-eung, and Gu Ja-yong. The team includes more executives and most of them are looking for additional investment in biotech.
A GS group official said, "Collaboration with DEXLEVO is one of our multiple strategies to secure sources of future growth, and we will continuously explore new businesses in various areas including the bio sector."
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005613/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Great Britain Leads Europe’s FMCG Inflation as NIQ Launches New Inflation Barometer6.8.2026 09:00:00 CEST | Press release
NIQ (NYSE: NIQ) today launches its new EU5 FMCG Inflation Barometer - a monthly tracker across five Western Europe markets – France, Great Britain, Germany, Italy and Spain – designed to help retailers, manufacturers and the media understand how inflation is evolving across Europe’s largest grocery markets and how shoppers are responding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806579111/en/ EU5 CPG Inflation slows to +1.1% The first edition of the Barometer reveals that while inflation across Europe’s FMCG sector remains relatively contained overall, significant differences persist between countries. Key findings include: Great Britain recorded the highest FMCG inflation across the EU5 at +2.3%1, above the European average of +1.1%. France and Italy reported the lowest inflation at -0.4% and +0.6% retrospectively, highlighting the uneven inflationary landscape across Europe's major economies. The monthly Barometer
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom